HBIO
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a deep discount to sales, but this is often a value trap in distressed healthcare micro-caps.
- Low P/S ratio (0.22)
- Reasonable P/B ratio (1.40)
- Lack of positive earnings (N/A P/E)
- No Graham Number available due to lack of earnings
Growth metrics are currently negative, making the forward P/E speculative.
- Forward P/E of 5.39 suggests expected return to profitability
- Negative YoY and Q/Q revenue growth
- Poor earnings surprise track record (1/4 beats in last 4 quarters)
Long-term historical performance is catastrophic.
- Recent 1-year recovery (+10.5%)
- 5-year return of -93.5%
- 3-year return of -91.5%
Fundamental health is weak; high leverage and poor efficiency scores.
- Current Ratio (2.20) is strong
- Piotroski F-Score of 2/9
- Debt/Equity of 3.22
- Negative ROE of -147.13%
Company is in no position to return capital to shareholders.
- No dividend paid
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HBIO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HBIO
Harvard Bioscience, Inc.
Primary
|
-93.5% | -91.5% | +10.5% | +2.6% | -15.5% | -17.1% |
|
AIDX
20/20 Biolabs, Inc.
Peer
|
-92.0% | -92.0% | -92.0% | -92.0% | -32.8% | +1.6% |
|
CUE
Cue Biopharma, Inc.
Peer
|
-98.5% | -94.2% | -69.9% | -75.0% | -37.5% | -18.2% |
|
GNTA
Genenta Science S.p.A.
Peer
|
-93.8% | -88.7% | -82.4% | -79.4% | -21.2% | -4.4% |
|
HIND
Vyome Holdings, Inc.
Peer
|
-100.0% | -100.0% | -96.1% | -56.8% | -15.1% | +2.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HBIO
Harvard Bioscience, Inc.
|
BEARISH | $19.27M | - | -147.1% | -65.5% | $4.31 | |
|
AIDX
20/20 Biolabs, Inc.
|
BEARISH | $19.95M | - | -503.1% | -182.8% | $1.91 | Compare |
|
CUE
Cue Biopharma, Inc.
|
NEUTRAL | $18.38M | - | -121.1% | -96.9% | $0.19 | Compare |
|
GNTA
Genenta Science S.p.A.
|
BEARISH | $16.02M | - | -38.0% | -% | $0.68 | Compare |
|
HIND
Vyome Holdings, Inc.
|
BEARISH | $15.37M | - | -% | -% | $2.19 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-17 | SNIDER WILLIAM | Director | Stock Award | 110,000 | - |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning HBIO from our newsroom.